PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter 2022 Financial Results

Rhea-AI Summary

PDS Biotechnology Corporation (Nasdaq: PDSB) is set to release its financial results for Q4 2022 on March 28, 2023, before market opening. A conference call will follow to discuss these results and provide a business update. The company is developing targeted immunotherapies for cancer and infectious diseases, utilizing its proprietary platforms, Versamune® and Infectimune™. Their lead candidate, PDS0101, has shown promise in reducing tumors in HPV16-related cancers. The conference call will be accessible via domestic and international numbers and a webcast will be archived for six months.

Positive

• Clinical candidate PDS0101 demonstrates ability to reduce tumors in HPV16-associated cancers.
• Development of robust and durable T cell responses shown in pre-clinical studies.

Negative

• None.

FLORHAM PARK, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that the Company will release financial results for the fourth quarter of 2022 on Tuesday, March 28, 2023, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update.

Tuesday, March 28, 2023, 8:00 AM EDT
Domestic: 877-407-3088
International: 201-389-0927
Conference ID: 13736455
Webcast: PDS Biotech Earnings Webcast

After the live webcast, the event will be archived on PDS Biotech’s website for six months.

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune^®, Versamune^® plus PDS0301, and Infectimune™ T cell-activating platforms. We believe our targeted immunotherapies have the potential to overcome the limitations of current immunotherapy approaches through the activation of the right type, quantity and potency of T cells. To date, our lead clinical candidate, PDS0101, has demonstrated the ability to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV16-associated cancers. Our Infectimune™ based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Investor Contacts:
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: pdsb@cg.capital

Media Contacts:
Tiberend Strategic Advisors, Inc.
Dave Schemelia
Phone: +1 (609) 468-9325
dschemelia@tiberend.com   

Bill Borden
Phone: +1 (732) 910-1620
bborden@tiberend.com

 

FAQ

When will PDSB release its Q4 2022 financial results?

PDSB will release its Q4 2022 financial results on March 28, 2023, before the market opens.

How can I listen to the PDSB financial results conference call?

You can listen to the PDSB financial results conference call at 8:00 AM EDT on March 28, 2023, using domestic and international phone numbers provided in the press release.

What is the focus of PDS Biotechnology's clinical development?

PDS Biotechnology focuses on developing targeted immunotherapies for cancer and infectious diseases based on their proprietary platforms.

What is PDSB's lead clinical candidate?

PDSB's lead clinical candidate is PDS0101, which targets HPV16-associated cancers.

Will the conference call be available for later listening?

Yes, the conference call will be archived on PDSB's website for six months after the live event.